Los Angeles, CA - 
(NewMediaWire) - April 23, 2021 - The Schall
Law Firm, a national shareholder rights
litigation firm, reminds investors of a class action lawsuit against FibroGen,
Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN) for violations of §§10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the
Company's securities between November 8, 2019 and April 6, 2021, inclusive (the
''Class Period''), are encouraged to contact the firm before June 11,
2021.
If you are a shareholder who
suffered a loss, click here to participate.
We also encourage you to
contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite
2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of
charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has
not yet been certified, and until certification occurs, you are not represented
by an attorney. If you choose to take no action, you can remain an absent class
member.
According to the Complaint, the
Company made false and misleading statements to the market. FibroGen’s past
disclosures of U.S. primary cardiovascular safety analyses from the Phase 3
program of roxadustat included post-hoc changes to the stratification factors.
The Company’s analyses with the original stratification factors resulted in
higher hazard ratios (point estimates of relative risk) and 95% confidence
intervals. The Company could not demonstrate that roxadustat reduces the risk
of or is a better treatment than MACE+ in dialysis, and MACE and MACE+ in
incident dialysis compared to epoetin-alfa. The Company faced uncertainty over
the approval of its NDA for Roxadustat by the FDA. Based on these facts, the
Company’s public statements were false and materially misleading throughout the
class period. When the market learned the truth about FibroGen, investors
suffered damages.
Join the case to
recover your losses.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE:
The Schall Law Firm
